Related Experiment Video
Updated: Feb 19, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
Vibor Milunović1,2, Martina Bogeljić Patekar1, Karla Mišura Jakubac1
1Division of Hematology, Merkur University Hospital, Zagreb, Croatia
Rituximab maintenance therapy improves progression-free survival in follicular lymphoma (FL) patients. While effective, its use in first-line settings and long-term benefits require further investigation amidst emerging treatments.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Rituximab, a CD20 antibody, has transformed non-Hodgkin lymphoma treatment.
- Follicular lymphoma (FL) is a common B-cell non-Hodgkin lymphoma.
Purpose of the Study:
- To review rituximab maintenance strategies in first- and second-line treatment of follicular lymphoma.
- To evaluate the impact of rituximab maintenance on patient outcomes.
Main Methods:
- Review of existing clinical data and studies on rituximab maintenance in FL.
- Analysis of progression-free survival and overall survival data.
Main Results:
- Rituximab maintenance improves progression-free survival in all FL patients.
- Overall survival is enhanced in the relapsed setting with rituximab maintenance.
- Controversies exist regarding first-line overall survival benefit and toxicity.
Conclusions:
- Rituximab maintenance is a rational option for FL patients responding to first-line therapy.
- It is particularly recommended for transplant-ineligible patients responding to reinduction therapy.
- Ongoing evaluation is needed considering novel agents and potential overtreatment.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis IV: Nursing Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease III: Medical Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...